Compare LMND & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LMND | TFX |
|---|---|---|
| Founded | 2015 | 1943 |
| Country | United States | United States |
| Employees | N/A | 14100 |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.4B |
| IPO Year | 2020 | N/A |
| Metric | LMND | TFX |
|---|---|---|
| Price | $75.76 | $123.01 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 8 | 10 |
| Target Price | $48.25 | ★ $139.88 |
| AVG Volume (30 Days) | ★ 2.3M | 740.3K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 1.11% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $658,300,000.00 | ★ $3,189,988,000.00 |
| Revenue This Year | $40.13 | $9.90 |
| Revenue Next Year | $59.80 | $10.51 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 33.66 | 5.42 |
| 52 Week Low | $24.31 | $102.58 |
| 52 Week High | $85.20 | $185.94 |
| Indicator | LMND | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 51.83 |
| Support Level | $80.22 | $120.77 |
| Resistance Level | $84.84 | $126.13 |
| Average True Range (ATR) | 5.40 | 3.83 |
| MACD | -0.71 | -0.35 |
| Stochastic Oscillator | 19.36 | 20.05 |
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes. The company is using technology, data, artificial intelligence, contemporary design, and social impact to deliver delightful and affordable insurances. Geographically, it operates in California, Texas, New York, New Jersey, Illinois, Georgia, Washington, Colorado, Pennsylvania, Oregon and others.
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.